Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
CONCLUSIONS: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.PMID:38052709 | DOI:10.1016/j.clml.2023.11.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 5, 2023 Category: Cancer & Oncology Authors: Thomas G Martin Philippe Moreau Saad Z Usmani Alfred Garfall Mar ía-Victoria Mateos Jes ús F San-Miguel Albert Oriol Ajay K Nooka Laura Rosinol Ajai Chari Lionel Karlin Amrita Krishnan Nizar Bahlis Rakesh Popat Britta Besemer Joaqu ín Martínez-López Source Type: research
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
CONCLUSIONS: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.PMID:38052709 | DOI:10.1016/j.clml.2023.11.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 5, 2023 Category: Cancer & Oncology Authors: Thomas G Martin Philippe Moreau Saad Z Usmani Alfred Garfall Mar ía-Victoria Mateos Jes ús F San-Miguel Albert Oriol Ajay K Nooka Laura Rosinol Ajai Chari Lionel Karlin Amrita Krishnan Nizar Bahlis Rakesh Popat Britta Besemer Joaqu ín Martínez-López Source Type: research
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research
REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation
J Clin Transl Sci. 2023 Oct 13;7(1):e219. doi: 10.1017/cts.2023.642. eCollection 2023.ABSTRACTREAP-2 is an interactive dose-response curve estimation tool for Robust and Efficient Assessment of drug Potency. It provides user-friendly dose-response curve estimation for in vitro studies and conducts statistical testing for model comparisons with a redesigned user interface. We also make a major update of the underlying estimation method with penalized beta regression, which demonstrates great reliability and accuracy in dose estimation and uncertainty quantification. In this note, we describe the method and implementation of...
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Xinying Fang Xinyi Liu Vernon M Chinchilli Michael Wang Hong-Gang Wang Nikolay V Dokholyan Chan Shen J Jack Lee Shouhao Zhou Source Type: research
EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
CONCLUSIONS: Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.PMID:38031139 | PMC:PMC10685657 | DOI:10.1186/s13148-023-01606-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Boheng Li Qidi Zhou Qin Wan Xuan Qiao Shangying Chen Jianbiao Zhou Zhijun Wuxiao Lei Luo Siok-Bian Ng Jieping Li Wee-Joo Chng Source Type: research
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research
REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation
J Clin Transl Sci. 2023 Oct 13;7(1):e219. doi: 10.1017/cts.2023.642. eCollection 2023.ABSTRACTREAP-2 is an interactive dose-response curve estimation tool for Robust and Efficient Assessment of drug Potency. It provides user-friendly dose-response curve estimation for in vitro studies and conducts statistical testing for model comparisons with a redesigned user interface. We also make a major update of the underlying estimation method with penalized beta regression, which demonstrates great reliability and accuracy in dose estimation and uncertainty quantification. In this note, we describe the method and implementation of...
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Xinying Fang Xinyi Liu Vernon M Chinchilli Michael Wang Hong-Gang Wang Nikolay V Dokholyan Chan Shen J Jack Lee Shouhao Zhou Source Type: research
EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
CONCLUSIONS: Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.PMID:38031139 | PMC:PMC10685657 | DOI:10.1186/s13148-023-01606-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Boheng Li Qidi Zhou Qin Wan Xuan Qiao Shangying Chen Jianbiao Zhou Zhijun Wuxiao Lei Luo Siok-Bian Ng Jieping Li Wee-Joo Chng Source Type: research
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research
REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation
J Clin Transl Sci. 2023 Oct 13;7(1):e219. doi: 10.1017/cts.2023.642. eCollection 2023.ABSTRACTREAP-2 is an interactive dose-response curve estimation tool for Robust and Efficient Assessment of drug Potency. It provides user-friendly dose-response curve estimation for in vitro studies and conducts statistical testing for model comparisons with a redesigned user interface. We also make a major update of the underlying estimation method with penalized beta regression, which demonstrates great reliability and accuracy in dose estimation and uncertainty quantification. In this note, we describe the method and implementation of...
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Xinying Fang Xinyi Liu Vernon M Chinchilli Michael Wang Hong-Gang Wang Nikolay V Dokholyan Chan Shen J Jack Lee Shouhao Zhou Source Type: research
EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
CONCLUSIONS: Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.PMID:38031139 | PMC:PMC10685657 | DOI:10.1186/s13148-023-01606-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Boheng Li Qidi Zhou Qin Wan Xuan Qiao Shangying Chen Jianbiao Zhou Zhijun Wuxiao Lei Luo Siok-Bian Ng Jieping Li Wee-Joo Chng Source Type: research
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research
REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation
J Clin Transl Sci. 2023 Oct 13;7(1):e219. doi: 10.1017/cts.2023.642. eCollection 2023.ABSTRACTREAP-2 is an interactive dose-response curve estimation tool for Robust and Efficient Assessment of drug Potency. It provides user-friendly dose-response curve estimation for in vitro studies and conducts statistical testing for model comparisons with a redesigned user interface. We also make a major update of the underlying estimation method with penalized beta regression, which demonstrates great reliability and accuracy in dose estimation and uncertainty quantification. In this note, we describe the method and implementation of...
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Xinying Fang Xinyi Liu Vernon M Chinchilli Michael Wang Hong-Gang Wang Nikolay V Dokholyan Chan Shen J Jack Lee Shouhao Zhou Source Type: research
EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
CONCLUSIONS: Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.PMID:38031139 | PMC:PMC10685657 | DOI:10.1186/s13148-023-01606-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Boheng Li Qidi Zhou Qin Wan Xuan Qiao Shangying Chen Jianbiao Zhou Zhijun Wuxiao Lei Luo Siok-Bian Ng Jieping Li Wee-Joo Chng Source Type: research
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research
